Literature DB >> 23558964

CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population.

Yan Huang1, Xin Liu, Xin Kuang, Duanfang Liao.   

Abstract

The CYP2D6 gene has been suggested to play an important role in the pathogenesis of lung cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of CYP2D6 T188C variant with lung cancer. Published literature from PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang data were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of nine studies (1,516 lung cancer cases and 1,950 controls) for CYP2D6 T188C variant were included in the meta-analysis. The meta-analysis indicated that compared with CYP2D6 TT genotype, non-TT genotype (CC or CT) was significantly associated with lung cancer in the Chinese (OR = 1.61, 95 % CI = 1.38-1.87, p < 0.001), with no evidence of between-study heterogeneity (I (2) = 0.0 %, p = 0.991). The sensitivity analysis indicated that the association was stable and no publication bias was detected. The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese. Further large-scale studies with the consideration for gene-gene/gene-environment interactions should be conducted to investigate the association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23558964     DOI: 10.1007/s13277-013-0755-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

Review 1.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

Authors:  L DiAnne Bradford
Journal:  Pharmacogenomics       Date:  2002-03       Impact factor: 2.533

2.  [A case-control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer].

Authors:  Zhanlin Guo; Qinghua Zhou; Wen Zhu; Dairong Li; Tianzhu Yuan; Yanping Wang; Xiaohe Chen; Lunxu Liu; Zhu Wu; Junjie Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2005-04-20

3.  [The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer].

Authors:  Wei-Ying Li; Bai-Tang Lai; Xiu-Ping Zhan
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2004-12

4.  [CYP2D6*10 polymorphisms and lung cancer susceptibility].

Authors:  Zhen Yan; Yi-Ming Wu; Yong-Jun Wu
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2008-10

5.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

Authors:  P M Christensen; P C Gøtzsche; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 8.  Metabolic polymorphisms.

Authors:  A K Daly; S Cholerton; W Gregory; J R Idle
Journal:  Pharmacol Ther       Date:  1993 Feb-Mar       Impact factor: 12.310

9.  Variants in folate pathway genes as modulators of genetic instability and lung cancer risk.

Authors:  Amanda L Piskac-Collier; Claudia Monroy; Mirtha S Lopez; Andrea Cortes; Carol J Etzel; Anthony J Greisinger; Margaret R Spitz; Randa A El-Zein
Journal:  Genes Chromosomes Cancer       Date:  2011-01       Impact factor: 5.006

10.  [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].

Authors:  Yan-Fei Gu; Zong-De Zhang; Shu-Cai Zhang; Su-Hua Zheng; Hong-Yan Jia; Shu-Xiang Gu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.